Evidence map›Paper›PMID 41637137›Full record

ArticleKidney3602026

Artificial Intelligence-Electrocardiography to Predict Incident Atrial Fibrillation and Clinical Outcomes in Kidney Transplant Recipients.

Isabel G Scalia, Juan M Farina, Mahmoud H Abdelnabi, Milagros Pereyra Pietri, Girish Pathangey, Ramzi Ibrahim, Kamal Awad, Mohammed Tiseer Abbas, Nima Baba Ali, Ahmed K Mahmoud and 16 more

Abstract read
In one paragraph

Article in Kidney360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Isabel G ScaliaDepartment of Cardiovascular Diseases, Mayo Clinic, Phoenix, Arizona.ORCID 0000-0002-6459-9767
Juan M FarinaDepartment of Cardiovascular Diseases, Mayo Clinic, Phoenix, Arizona.ORCID 0000-0002-5824-8485
Mahmoud H AbdelnabiDepartment of Cardiovascular Diseases, Mayo Clinic, Phoenix, Arizona.
Milagros Pereyra PietriDepartment of Cardiovascular Diseases, Mayo Clinic, Phoenix, Arizona.
Girish PathangeyDepartment of Cardiovascular Diseases, Mayo Clinic, Phoenix, Arizona.ORCID 0000-0002-7594-9056
Ramzi IbrahimDepartment of Cardiovascular Diseases, Mayo Clinic, Phoenix, Arizona.ORCID 0000-0003-0124-9513
Kamal AwadDepartment of Cardiovascular Diseases, Mayo Clinic, Phoenix, Arizona.
Mohammed Tiseer AbbasDepartment of Cardiovascular Diseases, Mayo Clinic, Phoenix, Arizona.ORCID 0009-0004-7212-435
Nima Baba AliDepartment of Cardiovascular Diseases, Mayo Clinic, Phoenix, Arizona.ORCID 0009-0004-3979-0609
Ahmed K MahmoudDepartment of Cardiovascular Diseases, Mayo Clinic, Phoenix, Arizona.
Said AlsidawiDepartment of Cardiovascular Diseases, Mayo Clinic, Phoenix, Arizona.ORCID 0000-0001-8750-7880
D Eric SteidleyDepartment of Cardiovascular Diseases, Mayo Clinic, Phoenix, Arizona.
Hicham Z El MasryDepartment of Cardiovascular Diseases, Mayo Clinic, Phoenix, Arizona.ORCID 0000-0002-2470-2862
Dan SorajjaDepartment of Cardiovascular Diseases, Mayo Clinic, Phoenix, Arizona.ORCID 0000-0003-1976-6420
Luis R ScottDepartment of Cardiovascular Diseases, Mayo Clinic, Phoenix, Arizona.ORCID 0000-0002-1010-1062
Kwan S LeeDepartment of Cardiovascular Diseases, Mayo Clinic, Phoenix, Arizona.ORCID 0000-0001-6302-9925
Yeoungjee ChoFaculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane, Queensland, Australia.ORCID 0000-0002-3502-9837
David W JohnsonFaculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane, Queensland, Australia.ORCID 0000-0001-5491-3460
Samy M RiadNephrology Division, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0001-5737-9742
Hani M WadeiNephrology Division, Department of Transplant Medicine, Mayo Clinic, Jacksonville, Florida.ORCID 0000-0003-4886-0897
Steven J LesterDepartment of Cardiovascular Diseases, Mayo Clinic, Phoenix, Arizona.
Chieh-Ju ChaoDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0001-6155-0266
Jae K OhDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
Chadi AyoubDepartment of Cardiovascular Diseases, Mayo Clinic, Phoenix, Arizona.
Girish K MourNephrology Division, Department of Internal Medicine, Mayo Clinic, Phoenix, Arizona.ORCID 0000-0003-3764-0047
Reza ArsanjaniDepartment of Cardiovascular Diseases, Mayo Clinic, Phoenix, Arizona.ORCID 0000-0001-7081-4286

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

key pointsAtrial fibrillation after kidney transplantation is common and is associated with poor prognosis. Artificial intelligence applied to 12-lead electrocardiograms pretransplant accurately predicts the risk of new-onset atrial fibrillation in our cohort. High-risk artificial intelligence electrocardiography score was independently associated with increased risk of mortality and allograft failure.

backgroundIncident atrial fibrillation (AF) is common after kidney transplantation (KTx) and is associated with worse clinical outcomes. Artificial intelligence electrocardiography (AI-ECG) algorithms have demonstrated efficacy in predicting risk of new-onset AF in the general population; however, their prognostic value in KTx recipients is relatively unknown.

methodsRetrospective analysis was conducted on KTx recipients without AF, with at least one pretransplant ECG between 2011 and 2021 across three tertiary centers in the United States (Mayo Clinic sites in MN, AZ, and FL). A previously validated AI-ECG algorithm estimated the probability of incident AF for each patient. Based on AI-ECG probabilities, patients were categorized into high-risk and low-risk groups, with the optimal AI-ECG score cutoff determined. The incidence of new-onset AF, allograft failure, and mortality was compared between groups.

resultsOverall, 6246 patients (age 53.5±13.8 years; 58.9% male) were included. Pretransplant AI-ECG probability of AF ≥5% was the optimal cutoff for high risk of incident AF (sensitivity 72%, specificity 62%). High-risk scores were associated with true new-onset AF at 30 days (adjusted hazard ratio [aHR], 2.89; 95% confidence intervals [CI], 2.05 to 4.09; P < 0.001), 3 years (aHR, 2.54; 95% CI, 1.99 to 3.26, P < 0.001), and 5 years post-transplant (aHR, 2.48; 95% CI, 1.99 to 3.09, P < 0.001). High-risk AI-ECG scores were also associated with increased mortality (aHR, 1.56; 95% CI, 1.30 to 1.88, P < 0.001) and overall allograft failure (aHR, 1.50; 95% CI, 1.30 to 1.75, P < 0.001) through the 5-year follow-up.

conclusionsThis pretransplant AI-ECG parameter identified patients at increased risk of new-onset AF post-KTx and provided prognostic utility. Overall, this easy to obtain tool allows for risk stratification of patients who may benefit from closer monitoring, targeted risk factor modification, and early intervention.

Indexed as

Artificial IntelligenceAtrial FibrillationElectrocardiographyKidney TransplantationPostoperative ComplicationsAdultAgedAlgorithmsFemaleHumansIncidenceMaleMiddle AgedPrediction AlgorithmsPredictive Value of TestsPrognosisartificial intelligencecardiovascular diseasekidney transplantation

Identifiers

PMID41637137
PMCPMC13229420

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.